NewsHK
LONDON — Johnson & Johnson Chairman and Chief Executive Joaquin Duato told executives at the WSJ Leadership Institute CEO Summit in London that curing certain cancers within the next 10 years is a realistic scientific target, pointing to advances in immunotherapy and the company's recent acquisition of Firefly Bio as evidence that the field has already shifted.
His remarks, made before a gathering of global business leaders in the British capital, signal a broader recalibration among major pharmaceutical companies away from treating cancer purely as a condition to be managed.
From Terminal Prognosis to Long-Term Remission Duato used multiple myeloma to illustrate how sharply treatment outcomes have improved.
Life expectancy for patients with the disease now stands at 10 years, against what he described as "only single years" previously.
Keep reading